2021
Rates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ
Talcott WJ, Miccio JA, Park HS, White AA, Kozono DE, Singer L, Sands JM, Sholl LM, Detterbeck FC, Mak RH, Decker RH, Kann BH. Rates of invasive disease and outcomes in NSCLC patients with biopsy suggestive of carcinoma in situ. Lung Cancer 2021, 157: 17-20. PMID: 34052704, DOI: 10.1016/j.lungcan.2021.05.028.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerBiopsy suggestiveInvasive diseaseSitu diseaseSquamous histologySurvival outcomesTumor sizeObserved cohortNational Cancer DatabaseExcellent survival outcomesHalf of patientsCell lung cancerMultivariable logistic regressionResection of lesionsAdenocarcinoma histologyDefinitive therapyNSCLC patientsOverall survivalLocal therapyRisk stratificationLung cancerCancer DatabaseResectionSurgical pathologyLesion size
2018
Variable impact of prior cancer history on the survival of lung cancer patients
Monsalve AF, Hoag JR, Resio BJ, Chiu AS, Brown LB, Detterbeck FC, Blasberg JD, Boffa DJ. Variable impact of prior cancer history on the survival of lung cancer patients. Lung Cancer 2018, 127: 130-137. PMID: 30642541, DOI: 10.1016/j.lungcan.2018.11.040.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerPrior cancer historyNational Cancer DatabaseCancer historyOverall survivalNSCLC patientsMultivariable Cox proportional hazards regression modelsTreatment approachesCox proportional hazards regression modelProportional hazards regression modelsKaplan-Meier survival curvesNSCLC patient survivalCell lung cancerHazards regression modelsLung cancer patientsPrior cancerPrior malignancyNSCLC survivalPatient survivalCancer patientsLung cancerCancer DatabasePatient's potentialPrior historyPatients
2016
The Natural History of Operable Non-Small Cell Lung Cancer in the National Cancer Database
Rosen JE, Keshava HB, Yao X, Kim AW, Detterbeck FC, Boffa DJ. The Natural History of Operable Non-Small Cell Lung Cancer in the National Cancer Database. The Annals Of Thoracic Surgery 2016, 101: 1850-1855. PMID: 27041452, DOI: 10.1016/j.athoracsur.2016.01.077.Peer-Reviewed Original ResearchConceptsOperable non-small cell lung cancerNon-small cell lung cancerNational Cancer DatabaseUntreated NSCLC patientsClinical stage ICell lung cancerNSCLC patientsNatural historyStage ILung cancerCancer DatabaseUntreated non-small cell lung cancerIIIA non-small cell lung cancerMultivariable Cox regression modelsLarge cell histologyNatural history cohortOperable NSCLC patientsCox regression modelMedian survivalUntreated patientsCell histologyMeier estimatesSurgical resectionClinical stageSquamous cells
2014
Impact of Adjuvant Treatment for Microscopic Residual Disease After Non-Small Cell Lung Cancer Surgery
Hancock JG, Rosen JE, Antonicelli A, Moreno A, Kim AW, Detterbeck FC, Boffa DJ. Impact of Adjuvant Treatment for Microscopic Residual Disease After Non-Small Cell Lung Cancer Surgery. The Annals Of Thoracic Surgery 2014, 99: 406-413. PMID: 25528723, DOI: 10.1016/j.athoracsur.2014.09.033.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerPositive surgical marginsCell lung cancerSurgical marginsR1 resectionNSCLC patientsResidual diseaseLung cancerNational Cancer Data BasePathologic stage IMicroscopic residual diseaseAdministration of chemotherapyOptimal treatment approachStage pIR1 patientsAdjuvant treatmentPostoperative administrationAdjuvant approachIncomplete resectionPostoperative radiationComplete resectionImproved survivalPI patientsPositive marginsSuperior survivalNow or Later: Evaluating the Importance of Chemotherapy Timing in Resectable Stage III (N2) Lung Cancer in the National Cancer Database
Boffa DJ, Hancock JG, Yao X, Goldberg S, Rosen JE, Kim AW, Moreno A, Detterbeck FC. Now or Later: Evaluating the Importance of Chemotherapy Timing in Resectable Stage III (N2) Lung Cancer in the National Cancer Database. The Annals Of Thoracic Surgery 2014, 99: 200-208. PMID: 25440272, DOI: 10.1016/j.athoracsur.2014.08.040.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNational Cancer DatabaseStage III non-small cell lung cancerPreoperative chemotherapyPostoperative chemotherapyLung cancerCancer DatabaseIII-N2 non-small cell lung cancerStage III lung cancerStage III NSCLC patientsTiming of chemotherapyCell lung cancerCox proportional hazardsSeparate Cox modelsNSCLC patientsChemotherapy resultsChemotherapy timingAdjusted comparisonsChemotherapy approachesChemotherapyCox modelProportional hazardsPatientsTumor attributesCStagePredictors of Mortality After Surgical Management of Lung Cancer in the National Cancer Database
Rosen JE, Hancock JG, Kim AW, Detterbeck FC, Boffa DJ. Predictors of Mortality After Surgical Management of Lung Cancer in the National Cancer Database. The Annals Of Thoracic Surgery 2014, 98: 1953-1960. PMID: 25443003, DOI: 10.1016/j.athoracsur.2014.07.007.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerNational Cancer DatabaseLobectomy/bilobectomyAdverse eventsSurgical resectionMultivariable analysisMale sexFacility volumeLung cancerCancer DatabaseLung cancer surgeryPredictors of mortalityRight-sided tumorsDay of surgeryCell lung cancerStandard of careExtended lengthLarge cancer registryPerioperative outcomesPrimary endpointNSCLC patientsSurgical complicationsWedge resectionSurgical treatmentCancer Registry
2012
Thoroughness of Mediastinal Staging in Stage IIIA Non-small Cell Lung Cancer
Vest MT, Tanoue L, Soulos PR, Kim AW, Detterbeck F, Morgensztern D, Gross CP. Thoroughness of Mediastinal Staging in Stage IIIA Non-small Cell Lung Cancer. Journal Of Thoracic Oncology 2012, 7: 188-195. PMID: 22134069, PMCID: PMC3253367, DOI: 10.1097/jto.0b013e318236ecbb.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overBiopsy, NeedleCarcinoma, Non-Small-Cell LungCohort StudiesComorbidityConfidence IntervalsGuideline AdherenceHumansLung NeoplasmsLymph NodesMediastinoscopyMediastinumMedicareMultivariate AnalysisNeoplasm StagingOdds RatioPositron-Emission TomographySEER ProgramSurvival AnalysisUnited StatesConceptsStage IIIA non-small cell lung cancerIIIA non-small cell lung cancerNon-small cell lung cancerInvasive stagingCell lung cancerMediastinal stagingLung cancerClinical stage IIIA non-small cell lung cancerEnd Results-Medicare databaseStage IIIA NSCLC patientsPositron emission tomography scanningPathologic lymph nodesIIIA NSCLC patientsMultivariable logistic regressionInvasive mediastinal stagingNSCLC patientsOlder patientsPatient characteristicsLymph nodesPatient factorsHistologic confirmationPractice patternsMedicare claimsMedicare beneficiariesPET scanning
2010
High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology
Anagnostou VK, Lowery FJ, Zolota V, Tzelepi V, Gopinath A, Liceaga C, Panagopoulos N, Frangia K, Tanoue L, Boffa D, Gettinger S, Detterbeck F, Homer RJ, Dougenis D, Rimm DL, Syrigos KN. High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. BMC Cancer 2010, 10: 186. PMID: 20459695, PMCID: PMC2875218, DOI: 10.1186/1471-2407-10-186.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedBiomarkers, TumorCarcinoma, Large CellCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellCell DifferentiationCohort StudiesConnecticutFemaleGreeceHumansKaplan-Meier EstimateLung NeoplasmsMaleMiddle AgedNeoplasm StagingPredictive Value of TestsProportional Hazards ModelsProto-Oncogene Proteins c-bcl-2Reproducibility of ResultsRetrospective StudiesRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUp-RegulationConceptsNon-small cell lung cancer patientsCell lung cancer patientsNon-squamous tumorsLung cancer patientsBcl-2 expressionNSCLC patientsCancer patientsBcl-2Favorable outcomeIndependent cohortSmall cell lung cancer patientsIndependent lower riskNon-squamous histologySubgroup of patientsHigh expressersSquamous cell carcinomaHigh Bcl-2 expressionBcl-2 protein levelsSquamous histologyMedian survivalPrognostic factorsValidation cohortCell carcinomaPathological characteristicsPrognostic stratification
2004
Induction and Concurrent Chemotherapy With High-Dose Thoracic Conformal Radiation Therapy in Unresectable Stage IIIA and IIIB Non–Small-Cell Lung Cancer: A Dose-Escalation Phase I Trial
Socinski MA, Morris DE, Halle JS, Moore DT, Hensing TA, Limentani SA, Fraser R, Tynan M, Mears A, Rivera MP, Detterbeck FC, Rosenman JG. Induction and Concurrent Chemotherapy With High-Dose Thoracic Conformal Radiation Therapy in Unresectable Stage IIIA and IIIB Non–Small-Cell Lung Cancer: A Dose-Escalation Phase I Trial. Journal Of Clinical Oncology 2004, 22: 4341-4350. PMID: 15514375, DOI: 10.1200/jco.2004.03.022.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic Combined Chemotherapy ProtocolsArea Under CurveCamptothecinCarboplatinCarcinoma, Non-Small-Cell LungCombined Modality TherapyFemaleHumansIrinotecanLung NeoplasmsMaleMiddle AgedNeoplasm StagingPaclitaxelRadiotherapy, ConformalRemission InductionSurvival AnalysisTreatment OutcomeConceptsStage III NSCLC patientsCell lung cancerClinical target volumeConcurrent chemotherapyConformal radiation therapyNSCLC patientsPerformance statusLung cancerRadiation therapyDose-escalation phase I trialTarget volumeConventional radiotherapy dosesUnresectable stage IIIAGood performance statusLocal control rateMaximum-tolerated doseDose-limiting toxicityPhase I trialMedian survival timeOverall response rateInitial clinical target volumeInduction chemotherapyFatal hemoptysisLate toxicityStage IIIA